GNPX:NASDAQGenprex, Inc. Analysis

Genprex (GNPX) is trading well below its 20‑day SMA (1.90) and 50‑day SMA (2.07) at $1.54, with the 200‑day SMA still at $6.95, indicating a deep bearish trend. The RSI sits at 30.5, flirting with oversold territory, while the MACD line remains under its signal, producing a bearish histogram. Volume has been decreasing, and the stock’s beta of 1.9 combined with a 30‑day volatility of nearly 98% underscores extreme price swings. Fundamentally, the company reports zero revenue, negative EBITDA of $‑15.5 M, and a trailing EPS of $‑17.40, leaving traditional valuation metrics (PE, price‑to‑sales) meaningless. The balance sheet shows only $7.8 M in cash against a market cap of $3.6 M, yielding a price‑to‑book of 0.41 versus a book value per share of $3.78. Recent material news highlights that collaborators will present positive pre‑clinical data on the lead candidate Reqorsa® at the AACR 2026 meeting, offering a potential catalyst despite the current technical weakness.
In summary, the stock is highly speculative with severe downside risk, yet a successful data read‑out could trigger a dramatic re‑rating, making it a classic high‑risk/high‑reward biotech play.